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TECHNICAL NOTE 
Kissing-Watchman technique applied in single-lobulated left atrial appendage 
anatomy with giant ostia 
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Linying Xia*, Yi Liu*, Ling Tao 
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 
Shaanxi, China 
 
Address for correspondence: Ling Tao, MD, PhD, Professor and Chief, Department of 
Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West 
Road, Xi’an 710032 China,, tel: 86-29-8477-5183, fax: 86-29-8321-1024, e-mail: 
lingtao@fmmu.edu.cn 
*The first two authors contributed equally to this work. 
 
 
Abstract 
Background: The Watchman device is the predominant occluder in China. However, 
the large left atrial appendage (LAA) ostium cannot be completely closed using a 
single Watchman device with the current sizes available. The aim of this pilot study 
was to evaluate the safety of the kissing-Watchman technique in single-lobulated LAA 
with large-ostia anatomy. 
Methods: Three out of 100 consecutive patients, who underwent kissing-Watchman 
occlusion under the guidance of transesophageal echocardiography (TOE), were 
included in this study. 
Results: All procedures were successful, with no severe complications. TOE 
performed three months after the procedure showed adequate LAA sealing, without 
thrombus formation on the devices. The 12-month follow-up was uneventful. 
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Conclusions: When necessary, the implantation of a kissing-device to achieve 
complete LAA occlusion in patients with single-lobulated left atrial appendage and 
giant ostia anatomy is safe and leads to favorable results during follow-up. Potentially, 
this technical innovation may widen Watchman indications in single-lobulated left 
atrial appendage with giant ostia anatomy. 
Key words: Watchman; kissing, left atrial appendage 
 
 
The only commercially available device in the documented institution is the 
Watchman (Boston Scientific, Marlborough, MA, USA) occluder which is the 
predominant occluder in China. The single device approach may not always fit the 
great anatomic variability of the left atrial appendage (LAA). Adequate closure may 
require more than a single device. The commercially available Watchman device only 
fits LAAs with a maximum diameter of 30 mm [1–3]. In patients with bilobulated 
LAA, the one-stop implantation of double Watchman is feasible as reported by a 
previous study [4]. However, it is unknown whether this approach is feasible in the 
setting of a single-lobulated LAA with a giant ostium (>30 mm). Reported herein, is a 
consecutive case series of patients in whom kissing-Watchman was performed to 
achieve adequate closure of the single-lobulated LAA with large-ostium.  
Three out of 100 consecutive patients underwent kissing-Watchman occlusion 
under the guidance of transesophageal echocardiography (TEE). This experimental 
procedure was preceded with the patient’s acceptance. Before intervention, TEE was 
performed to exclude thrombi in the LAA. The procedures were performed via 
femoral access under general anesthesia, and were controlled by the angiography and 
TEE. At the beginning of the intervention, 5000 units of heparin were given. After 
transseptal passage, TEE measurement of the LAA diameter at the intended 
implantation site was performed at four different angles. According to the three cases, 
the maximal LAA ostia diameters were 35, 36, and 33 mm, respectively. The first 
occluder was deemed to cover half of the estimated LAA orifice area (d1 = 
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LAAmax/√2). Additionally, the size of the first Watchman device should be greater 
than or equal to the size of the second device. The second occluder was chosen based 
on residual space. The first Watchman device was pre-released and held still at the 
intended implantation site (Fig. 1A). After another transseptal puncture via the same 
femoral site, the pigtail catheter with the second access sheath was delivered carefully 
to the uncovered space parallel to the first access sheath and contrast injection was 
made (Fig. 1B). Excessive adjustment was avoided in order to minimize the 
sheath-sheath interplay. The second Watchman device was chosen according to the 
residual stump and was carefully placed next to the first device in a kissing fashion. 
Two Watchman devices were deployed adjacently. Therefore, complete LAA closure 
was achieved. Fluoroscopy and TEE were used to confirm the position, size and seal 
of the kissing device. The tug-test was performed on the two devices by pulling the 
parallel the parallel and deliver the system simultaneously to avoid dislocation (Fig. 
1C). The two devices were released respectively after the PASS criteria had been met 
(Fig. 1D). The final diameters of each kissing-Watchman deployed were measured by 
TEE and the maximum device compression ratio of the kissing-Watchman LAA 
closure should be larger than a single device LAA closure technique (the upper limit 
was not limited to 30%). This higher compression ratio contributed to a more radical 
deformation of the kissing-device on the mutual compression side reducing the 
possibility of inter-device residual flow. Larger endotheliazation area of the kissing 
device contributes to prolongation of antithrombotic/antiplatelet therapy (3-month 
antithrombotic therapy or 12-month antiplatelet therapy). TEE 3-month and 12-month 
was scheduled after kissing-Watchman implantation. 
The first patient was a 70-year-old male with a CHA2DS2-VASc score of 3. He 
was referred for LAA closure due to gastrointestinal bleeding on Warfarin. TEE 
showed a single lobe LAA with a maximum LAA ostium of 35 mm (Suppl. Fig. 1A). 
In a single intervention, the giant LAA was partially closed by the implantation of a 
27 mm Watchman, and the remaining ostium with a diameter of 12.3 mm was closed 
by implantation of another 21 mm Watchman (Suppl. Fig. 1B). TEE showed that the 
maximum device compression ratio of the kissing-Watchman LAA closure was 19% 
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and a complete LAA closure was achieved (Suppl. Fig. 1C, D). The patient was 
placed on full dose rivaroxaban for three months after the intervention and dual 
antiplatelet therapy daily afterwards. A TEE performed three months later showed 
good position of both devices, with a newly formed gap of 4.6 mm (Suppl. Fig. 1E). 
The patient remained asymptomatic. Twelve months after the intervention, TEE 
confirmed an adequate occlusion with a remarkably shrinking peri-device flow of 1.8 
mm and no device related thrombus was identified (Suppl. Fig. 1F). 
The second patient was a 55-year-old male patient who underwent closure of a 
giant single-lobulated LAA due to paroxysmal atrial fibrillation, CHA2DS2-VASc 
score of 4, and recurrent stroke under Warfarin. TEE showed a single lobe LAA with 
a maximum LAA ostium of 36 mm without a ridge-like pectinate muscle inside 
(Suppl. Fig. 2A). Knowing that two devices would be necessary, the giant LAA was 
partially closed by implantation of a 27 mm Watchman leaving a 24 mm opening 
stump (Suppl. Fig. 2B). Therefore, complete LAA closure was achieved by the 
subsequent implantation with an additional 27 mm Watchman (Suppl. Fig. 2C, D). 
The maximum device compression ratio of the kissing-Watchman system was 33.3%. 
The patient was discharged on 110 mg dabigatran bid for the first 3 months 
post-operation and dual antiplatelet therapy for the following 8 months. TEE 3-month 
and 1-year post-operation follow-up showed adequate LAA sealing, with a persistent 
residual flow of 1.6 mm in the LAA and no device related thrombus was identified 
(Suppl. Fig. 2E, F). One year after the intervention the patient remained free of 
symptoms on acetylsalicylic acid 100 mg daily indefinitely.  
The third patient was a 78-year-old man with a previous stroke, a 
CHA2DS2-VASc score of 4, and chronic kidney disease precluding the use of 
Warfarin. TEE demonstrated a large single-lobulated LAA with a 33 mm ostium and 
many pectinate muscles deep inside (Suppl. Fig. 3A). Knowing that two devices 
would be necessary, 27 mm Watchman was placed at the entrance of the LAA. It 
partially occluded LAA with a 14 mm residual stump uncovered (Suppl. Fig. 3B). A 
subsequent implantation with an additional 21 mm Watchman was achieved to 
completely occlude this large LAA (Suppl. Fig. 3C–E). The maximum compression 
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ratio of the kissing-Watchman system was 28.6%. The patient was prescribed with 
dual antiplatelet daily for the following 12 months, post-implantation. TEE performed 
after 3 months showed good position of both devices, with no evidence of residual 
shunt (Suppl. Fig. 3F). The clinical follow-up was uneventful.  
There is a myriad of variations of LAA anatomy in terms of number of lobes and 
size of orifices [5]. One restriction inherent in single-device LAA occlusion technique 
concerns the maximum LAA body size suitable for intervention. Though there are 
larger sizes in other devices nowadays, the largest commercially available Watchman 
device only fits LAA with a maximum diameter of 30 mm [1]. Therefore, for an LAA 
ostium > 31 mm, it is difficult to obtain complete closure with a single Watchman 
device. The implantation of double Watchman is recommended in bilobulated LAA 
anatomy [1–3]. It remains controversial whether kissing-device, deployed adjacently 
in the same lobe is safe. Some scientists argue that there are several potential 
procedural risks [4]: 1) A severe residual flow between devices can exist; 2) the 
fixation barbs may injure the permeable polyester polyethylene (PET) membrane of 
the first device while deploying the second device; 3) due to the long-term mechanical 
interaction, device embolization may occur. In a considered opinion, to avoid 
potential peri-operative complications, it is important to: 1) select the kissing-device 
of identical or similar size to facilitate closer contact between the two devices 
minimizing residual shunting between them; 2) a more liberal oversizing technique 
(higher compression ratio) helps to minimize inter-device flow and also contributes to 
a greater radial force for stability; 3) deformation of the kissing-device on the mutual 
compression side contributes to minimizing potential leak between the 
kissing-devices. 
No device dislocation, severe residual flow (> 5 mm) or device related 
thrombosis was observed, aside from the minor (< 3 mm) peri-device leakage 
identified at both 3-month and 12-month TEE follow-up. It was reported that, in 
patients who had undergone single Watchman LAA closure, an intraprocedural gap 
could persist, and could close or close and reopen during the follow-up period [6]. 
Therefore, in patients who underwent kissing-Watchman implantation, a mild 
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peri-device leak during TEE follow-up may not be related to interaction between the 
devices. Additionally, a peri-device gap with mild blood leak may not affect the 
stability of the Watchman device inside LAA, as evidenced by the fact that no device 
dislodgement occurred in patients of the present study.  
Due to individual anatomic variations, a single Watchman device may not always 
adequately seal the LAA. In these cases, implantation of kissing-Watchman in 
single-lobulated LAA with giant ostia may afford a good anatomical result. Larger 
cohorts are needed to corroborate the safety and efficacy of this technical innovation.  
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Figure 1. Diagram of kissing-Watchman technique; A. The first device is pre-released 
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and held still at the intended implantation site, leaving a residual stump uncovered; B. 
The second access sheath is delivered to the uncovered space parallel to the first 
access sheath; C. The tug test is performed on the kissing-devices simultaneously; D. 
The two devices are released after the PASS criteria have been met.  

